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Abstract
Introduction Cerebral embolism is the principal cause of
cerebral infarction. Recently, mechanical embolectomy has
been proposed as an effective method. We performed a
preclinical evaluation of a new mechanical clot-retrieving
wire.
Methods This clot-retrieving wire consisted of three nitinol
loops at the tip of a microguidewire. These three loops
could be collapsed into a 0.018-inch wire compatible
microcatheter. Each loop was 8 mm long and 3.5 mm
wide. For simulation, polyvinyl alcohol (PVA) vascular
anatomical models of the human carotid (eight models) and
vertebrobasilar (three models) circulation were constructed.
A pulsatile flow circulation system was used. Embolic clots
were produced using pig blood plasma. The microcatheter
and the microguidewire were advanced beyond the clot.
The wire was then exchanged for the retrieving wire. The
microcatheter was then pulled slightly back to open the
loops. The clot was then caught by withdrawal of the system.
Once caught, the clot was retrieved to the guiding catheter
tip. We investigated the following points: ease of device
deployment, clot capture ability, clot removal against
blood flow and removal of the clot out of the introducer
system.
Results A total of 104 procedures were performed in 11
PVA models and evaluated. The drop rate was 19%. We
succeeded in partial and total recanalization in 51.0% of the
procedures (53/104) within 30 minutes.
Conclusion This new clot-retrieving wire could be useful
for mechanical clot extraction in stroke.
Keywords Mechanical thrombectomy . Clot .
Cerebral artery . Vascular model . Recanalization
Introduction
Embolism from a proximal source is the leading cause of
cerebral infarction. Embolism must be considered if a
patient with arrhythmia presents with acute neurological
signs. Stroke is associated with a short window of
opportunity for treatment. In order to dissolve the clot,
various approaches have been tried, such as the intravenous
administration of streptokinase [1–5] or urokinase [6, 7],
intraarterial administration of urokinase [8, 9] or pro-
urokinase [10, 11], intravenous administration of tissue
plasminogen activator (t-PA) [12–17] and intraarterial
administration of t-PA [18–20]. Recanalization rates and
final outcomes in the patients have been slightly improved,
but with an increase in the incidence of hemorrhage.
Moreover, some patients cannot be treated by any throm-
bolytic agent because of contraindications to therapy. New
methods are required to treat these patients.
Recently, mechanical embolectomy has been shown to
be a rapidly effective method for reducing cerebral
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hemorrhage induced by the thrombolytic agent. It also
allows patients to be treated outside the therapeutic window
and might globally improve treatment of embolism, when
compared to thrombolysis alone. At present, clot-removal
devices are under development. Some devices are based on
a vacuum system [21–23]; others use ultrasonic vibration
[24–27]. However, devices with complex systems are often
too stiff to insert into the cerebral vasculature. Indeed,
flexibility and simplicity of use are very important for clot
removal from cerebral arteries. A few devices are now
commercially available [28–30]. The recanalization rate of
target vessels was found to be of 53.5% in a recent study
concerning the MERCI device, which might be insufficient
for a medical device. Therefore, a new device which has a
high efficacy is needed.
A simple and small neuroendovascular clot retrieving
device for use in the cerebral vasculature has been
developed by the Terumo Corporation (Tokyo, Japan).
Before it can be introduced clinically, this device has to be
investigated regarding its ease of use, efficacy and safety.
We chose to investigate its use in polyvinyl alcohol (PVA)
hydrogel vascular models. Indeed, there are no animal
models which have a suitable vessel size and geometric
characteristics for this study. We also investigated how a
clot can be caught by the new device, and how this
procedure may fail.
Materials and methods
Polyvinyl alcohol hydrogel vascular models
PVA models pf the cerebral vasculature [31] were used for
the test. In some previous studies of devices, glass or
silicon models have been used. Glass models [32, 33] are
too rigid and silicon models [34–36] have high wall
friction. The friction of the device against the silicon wall
is much higher than against the wall of a PVA model, as
well as higher than against the human vessel wall [31].
Therefore, we preferred PVA models to silicon or glass
models.
We utilized a total of 11 PVA models from Elastrat
(Geneva, Switzerland) to test the effects of vessel tortuos-
ity, the effects of the presence of side branches, and the
effects of blood flow in dominant vessels and of collateral
flow in accordance with our experience (Fig. 1).
For the vertebrobasilar system, we used three models:
No. 1 Symmetrical smooth model
No. 2 Asymmetrical tortuous model, type A (contralat-
eral dominant vessel)
No. 3 Asymmetrical tortuous model, type B (ipsilateral
dominant vessel)
Fig. 1 Cerebral vascular PVA models (three vertebrobasilar artery and eight anterior circulation)
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For simulations involving the middle cerebral artery
(MCA), we used eight models (ACA anterior cerebral
artery, Pcom posterior communicating artery):
No. 4 Short MCA model with bifurcation and an anterior
communicating artery, with an ACA, without a
Pcom
No. 5 Long MCA model with trifurcation and a Pcom,
and a small ACA
No. 6 Long MCA model with bifurcation and a Pcom,
and a large ACA
No. 7 Long MCA model with bifurcation and a Pcom,
and a large ACA (tortuous type)
No. 8 Long MCA model with bifurcation and a Pcom,
and a large ACA (very tortuous type)
No. 9 Long tortuous MCA model with bifurcation and a
Pcom, with a large ACA (very tortuous type)
No. 10 Long tortuous MCA model with bifurcation and a
Pcom, with a large ACA
No. 11 Long MCA model with early bifurcation and a
Pcom, with a large ACA
Tested devices
The tested clot-retrieving wire consisted of three nitinol
loops at the tip of a 0.014-inch microguidewire (Fig. 2).
These three loops were mounted like a tulip at the tip of the
microguidewire and they could be collapsed to fit into a
0.018-inch wire compatible microcatheter. The loop was
8 mm long and 3.5 mm wide. Once the three loops had
been released from the microcatheter, the two side loops
opened like a flower due to their memorized shape. The
center loop was rendered radioopaque by the presence of a
titanium filament. Clot extraction with this device was
comparable to that using a lasso.
Pulsatile flow was produced by a pump (Iwaki magnetic
pump, Iwaki, Tokyo, Japan) which simulates physiological
blood pressure and collateral flow. The following parame-
ters were used: frequency 60 Hz, wave form pattern CB2,
amplitude 1.0 V.
The following microguidewires were used: GT wires
0.012 and 0.016 inch (Terumo), Transend 0.014 inch
(Boston Scientific Target, Fremont, Calif.), and SilverSpeed
0.010 inch (MicroTherapeutics, Irvine, Calif.). The follow-
ing microcatheters were used: Progreat 2.4F and 2.7F
(Terumo), FasTracker 18 (Boston Scientific Cork, Cork,
Republic of Ireland) and Rapid Transit (Cordis, Miami,
Fl.). The following guiding catheters used were: 6F Envoy
MPD, 8F Vista Brite tip MDA1 and 9F Vista Brite tip
MDA1 (Cordis), and 9F PATLIVE (Clinical Supply, Gifu,
Japan). The Introducing sheaths used were 6F and 8F Brite
tip sheath introducers (Cordis, Roden, The Netherlands).
The results for each combination of devices were not
recorded separately because the operating procedures were
modified according to the previous test results.
The tests were performed on a biplane digital subtraction
angiography unit (Integris V 3000; Philips Medical Sys-
tems, Best, The Netherlands). The contrast agent used was
either Iopamiro 300 (Bracco, Milan, Italia) or Omnipaque
350 (Schering Schweiz, Zurich, Switzerland). For training,
a few procedures were performed in each model by direct
viewing without fluoroscopy.
Fig. 2 Clot-retrieving wire (Terumo, Tokyo, Japan)
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Clots
The clots were produced from swine blood. First blood was
collected without heparin. Then 45 ml blood was added to
5 ml citric acid 3.8% (total 50 ml) (removal of calcium by
citric acid), and the mixture centrifuged (3000 rpm, 10 min,
room temperature). The plasma was then extracted and 5 ml
was mixed 45 ml lactic acid Ringer's solution 45 ml), and
the mixture stirred (chelating with calcium). Finally the
fibrin lump is picked and trimmed. Clots of any size could
be produced from the fibrin lump, and depending on the
amount of calcium used, clots could be softer or harder.
Test methods
For simulation of commonly encountered clinical condi-
tions, the in vitro vascular models described above were
constructed. Low-friction, transparent PVA vascular models
were used and integrated into a pulsatile flow system
providing physiological conditions. Embolic debris was
simulated by introducing fibrin clots obtained from pig
blood plasma hardened with lactic acid. The clot location
was recorded and clot retrieval with the wire was attempted
through both braided and nonbraided microcatheters. The
microguidewire-microcatheter system was advanced such
that the tip position reached distal to the clot. The regular
wire was then exchanged for the retrieving wire system to
reach the tip of the microcatheter. The microcatheter was
then pulled slightly back to allow opening of the loops. The
clot was caught by progressively withdrawing the system.
Once caught, the clot was retrieved into the guiding
catheter tip (Fig. 3).
We investigated the following points: (1) ease of device
deployment; (2) clot capture ability; (3) clot removal against
blood flow; and (4) removal of the clot out of the introducer
system. A total of 104 procedures in 11 PVA models were
performed and evaluated. All procedures were performed by
well-trained neuroendovascular surgeons (Dr. Hasan Yilmaz,
Dr. German Abdo and Dr. Fumio Asakura, Neuroradiology
Section, Geneva University Hospital). They chose a combi-
nation of devices (clot-retrieving wires, microcatheters,
guiding catheters, introducing sheaths) and modified the
operation procedures based on their personal experience.
First, we performed procedures in simple PVA models
with small and soft clots. Then, gradually, we performed
procedures in more complicated models with larger and
harder clots. Intentionally, we also tried to perform
procedures in more difficult situations which we devised.
We did this in order to determine which elements affected
the difficulty of clot retrieval. In order to determine our
learning curve, we measured the time for the procedure
from insertion of the microcatheter to retrieval of a clot
through the introducer in the last five procedures.
We observed the following effects:
1. Effects of vessel geometry on the device: Cerebral
vessels are very tortuous which renders insertion of
devices difficult. In order to reach a clot located in a
cerebral artery, the device must be inserted and guided
through the tortuous vessels. When the clot is removed,
it has to pass through the angles, bifurcations and the
orifices of branches. We evaluated the influence of
vessel geometry on the device.
2. Blood flow effects: The clot is pushed forward by the
strong blood flow. Thus, clot retrieval has to be done
against the blood flow. We evaluated the influence of
blood flow on clot retrieval.
3. Clot quality: The quality of a clot depends on many
factors (platelets, fibrin, etc.). The hardness of clots is
influenced by the different constituents. We took clot
consistency into consideration before retrieval.
4. Compatibility of the device with other devices: In order
to effectively use the device, an introducing sheath, a
guiding catheter and a microcatheter are needed. We
evaluated the compatibility between the device and
these other components.
Results
We were able to achieve recanalization in 53 out of 104
procedures. Thus the total or partial recanalization rate
(TIMI grade 2–3) was 51.0%. However, the clot retrieval
rate was 31.7%, because we lost clots during retrieval in 20
procedures (19.2%). In these cases, clots were washed
away to other vessels or dropped in the introducing sheath.
The failure rate was 49.0% (51 of 104 procedures; Table 1).
The time for recanalization of the target vessels varied
between 9 min 34 s and 21 min 23 s (average 14 min 51 s)
for the last five procedures (Table 2). In the final procedure,
we could not recanalize the target vessel within 30 min and
we stopped the procedure.
We present in the following sections a comparative
evaluation of the various devices used as components of the
system.
Microguidewire Initial passage through the clot-occluded
vessel segments was easiest to perform with the Terumo GT
wire 16, whereas the Transend 14 and SilverSpeed 10 wires
could hardly pass the side of the clot when the target vessel
was completely occluded by the clot.
Microcatheter It was very difficult to use the clot-retrieval
wire through nonbraided microcatheters (FasTracker 18) in
tortuous vessels because of strong friction, likely due to
catheter lumen deformation in tightly curved vessel seg-
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ments. However, braided microcatheters allowed access
without difficulty even in tortuous vessels. Moreover,
navigability was excellent with the Progreat catheter.
Guiding catheter Clots were more stable at the tip of the 8F
catheter than at the tip of the 6F catheter. Hard clots could
hardly be taken into the 8F catheter (Fig. 3a and b). When
we lost a clot from the clot-retrieval wire around the
guiding catheter tip with balloon during flow control, we
were able to catch the clot by aspiration through the guiding
catheter (Fig. 3c and d).
Introducing sheath Sometimes we lost a clot from the tip of a
6F introducer because the clot would often not be completely
loaded into the 6F guiding catheter; this would occur with the
8F introducer at the level of the valve, where we could not
squeeze and load the clot completely into the guiding catheter.
Clot-retrieving wire Clot-retrieving wires never broke. It
was very difficult to catch the clots at T-shaped junctions
and around sharp corners. We were able to retrieve clots
which were larger than the loops of the clot-retrieving wire.
Sometimes, we lost a clot at the orifice of the branches, at
sharp curves and in widely spread vessels. The clot-
retrieving wire had better radioopacity than another
comparator clot-retrieving device (Fig. 4).
Discussion
Intravenous administration of t-PA within 3 hours of the
onset of ischemic stroke has shown to result in an
improvement in clinical outcome at 3 months, despite an
increased incidence of symptomatic intracerebral hemor-
Fig. 3 a, b A hard clot is broken at the tip of a 6F guiding catheter or 6F introducer. c, d A soft clot is able to go into an 8F guiding catheter when
it is squeezable. e–h Effect of flow control by a guiding catheter with a balloon
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rhage [12]. To reduce the incidence of hemorrhage, direct
administration of the thrombolytic agent via a microcatheter
has been tried. In the PROACT I trial, the recanalization
rate of patients treated with pro-urokinase was 57.7%
compared to 14.3% for the control group. However,
hemorrhage with clinical deterioration within 24 hours
occurred in 15.4% of the pro-urokinase group compared to
7.1% for the control group [10]. In the PROACT II trial, the
recanalization rate was 66% with pro-urokinase associated
with heparin, compared to 18% for the group which
received heparin alone. However, hemorrhage with clinical
deterioration within 24 hours occurred in 10% of the pro-
urokinase and heparin group, compared to 2% for the
control group [11]. The efficacy of intraarterial adminis-
tration of t-PA remains controversial. Moreover, there
are patients who are seen within the 3-hour therapeutic win-
dow with contraindications to receiving any thrombolytic
agent.
Mechanical embolectomy has been proposed as a rapid
and effective means for recanalization. Usually, mechanical
embolectomy can be performed with a small amount of
heparin during the procedure. This may reduce the
incidence of hemorrhagic events. Therefore, patients, who
are in the hyperacute stage of cerebral stroke but who have
some kind of contraindication to thrombolytic therapy can
be treated by mechanical embolectomy.
There are a few commercially available mechanical clot-
retrieving devices for cerebral stroke, including the Merci
retriever (Concentric Medical, Mountain View, Calif.) and
the Catch system (Balt, Montmorency, France) [28–30].
Unfortunately, we could not acquire these devices for these
test for comparison. Also, from a technological point of
view, it might be interesting to develop a device with a
thinner wire. Furthermore, as with the Merci device, we
believe that this new system should be used together with a
distal balloon-mounted guiding catheter in clinical practice
and we would recommend it strongly. However, in this in
vitro study, stopping the pump corresponds to the temporal
occlusion obtained with a distal balloon-mounted guiding
catheter, thus reducing the risk of clot loss during the
retrieval step.
The total and partial recanalization rate (TIMI grade 2–
3) using the clot retrieval device was 51.0% (53/104
procedures), which at first glance seems to be low.
However, the recanalization rate was 53.5% in the MERCI
trial [30], which was an in vivo trial. We performed all
procedures in vitro using models. We used fibrin clots from
pig blood and saline for circulation in the PVA models. To
occlude the vessels in the PVA models we had to use clots
which had a diameter 1.2–1.5 times larger than the vessels.
In PVA models with saline, there is no adhesive material,
which is why we needed to use large clots. In fact, small
microguidewires which had spring tips could not pass the
side of the clots. In our models, flow pressure caused the
Table 1 Results of all procedures in all PVA models
Model
number
Procedures Total or partial
recanalization
Failurea Droppedb
4 4 1 3 1
1 4 1 3 1
6 8 7 1 3
3 4 3 1 0
7 10 6 4 1
2 7 5 2 2
2 8 5 3 5
10 9 7 2 3
5 4 0 4 0
5 7 6 1 1
9 6 4 2 1
8 10 2 8 0
11 23 6 17 2
Total 104 53 51 20
aWe could not catch the clot with the clot-retrieving wire.
bWe dropped the clot after catching it during the procedure.
Table 2 Time for the procedures in PVA model no. 11
Trial Procedure Time to
catch the
clot (min/s)
Time to
remove the
clot through
the introducer
(min/s)
Result
1 1 6/50 9/34 Total removal
2 1 – – Failure
2 – – Failure
3 – – Failure
4 – – Failure
5 10/20 11/56 Total removal
3 1 – – Failure
2 – – Failure
3 – – Failure
4 10/45 12/27 Half the clot
removed
5 – – Failure
6 – – Failure
7 20/1 21/23 Total removal
4 1 – – Failure
2 9/55 – Dropped
3 – – Failure
4 – – Failure
5 – – Failure
6 14/51 16/30 Total removal
5 1 – – Failure
2 – – Failure
3 – – Failure
4 – – Procedure stopped
(>30 min)
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clots to occlude the vessel tightly because the PVA surface
was very smooth. Usually, in the clinical setting we can
maneuver a microguidewire with spring tips past the side of
a clot during thrombolysis. Therefore, the situation we
encountered in the PVA model seemed to be more difficult
than in humans.
We tried to simulate many difficult situations that might
arise in clinical practice to establish the limitations of the
clot-retrieving wire. We performed procedures several times
under the same conditions when we failed, in order to
determine the reason for the failure. To confirm the effect of
clot hardness, we used some hard clots made from swine
fibrin and calcium. They were hard as a stone. It was quite
difficult to catch such a clot, because the loops slipped on
the surface of the clot.
To determine the best guiding catheter size for the
device, various sizes were used for the test. First, we used a
6F guiding catheter, because the 0.018-inch wire compat-
ible microcatheter needed a 5–6F guiding catheter. But
clots were hardly removed through a 6F catheter. The
diameter of target vessels is around 3.0–4.0 mm, which is
larger than the inner diameter of a 6F guiding catheter and
introducer. It seems a little bit larger than the inner diameter
of an 8F guiding catheter and introducer. Most clots can be
squeezed to a degree to enter the lumen of an 8F introducer
sheath that has an internal diameter of 2 mm. When clots
could be squeezed into the lumen, we could put them into
the 8F guiding catheter. Therefore, we recommend using at
least an 8F guiding catheter and introducer with this
device.
To stabilize the clots at the tip of the guiding catheters,
strong manual aspiration through the guiding catheters was
performed. To catch a clot, the retrieving device should be
pulled while keeping the position of the microcatheter
stable in order to make the loops smaller. Very fragile clots
were fragmented by the loops. Besides these problems
related to the clots themselves, we did not encounter any
problems that we consider to have been related to the
system design.
When clots fragmented at the tip of the guiding catheter,
aspiration through the guiding catheters and introducers
was also performed to remove the fragments. In order to
develop a standard procedure with this device, some
procedures were considered wasted for training. These
failures were included. Therefore, we can expect higher
recanalization rates in humans.
The main limitations of this study are the absence of
comparison with other devices and no numerical evaluation
of success. Regarding the absence of comparative data with
other devices, we performed this test to observe and
evaluate how the new device worked in vitro. We also
had to define the interventional procedure, because our test
was the first for this device. On the other hand, the
interventional procedures for the Merci retriever and Catch
system are well known. Therefore, we did not compare the
new device with others. Regarding the absence of numer-
ical evaluation, except for success rate and procedure time,
the main purpose of this test was to observe how the new
device worked in various situations, and to define an
operating procedure with suitable devices. Combinations of
devices and operating procedures were modified many
times. Therefore, we do not have sufficient quantitative data
for the same situation.
Conclusion
This new clot-retrieving wire was developed with the
technology based on the 0.018-inch microguidewire for
intracranial vessels. Various characteristics were observed
with preclinical testing in human-like in vitro PVA models.
The recanalization rate within a 30-minute time limit using
the Terumo clot-retrieving wire was over 50%. The
performance of the device in this preclinical test was
encouraging and justifies progressing to a feasibility test in
a clinical setting without hesitation. Also the use of PVA
models allows animal testing to be avoided or at least to be
used only at a later stage to test the devices.
Conflict of interest statement We declare that we have no conflict
of interest.
Fig. 4 Radiographs of clot
retrievers in PVA model no. 11
(left new Terumo clot-retrieving
wire, right Catch clot-retrieving
wire (Balt, Montmorency,
France)
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